Our diagnostic and therapeutic solutions
Stallergenes Greer supports allergists and patients at each stage of allergen immunotherapy treatment. Our comprehensive and consistent portfolio is adapted to the individual needs and profile of each patient and covers a broad variety of allergens.
Spanning source materials, routes of administration, cutting-edge delivery mechanisms and finished products, Stallergenes Greer’s innovative diagnostic tools and allergen immunotherapy (AIT) solutions are designed to improve ease of access and treatment outcomes.
Diagnosis
The diagnosis of respiratory allergies is based on clinical history, physical examination, allergy tests and specific questions. One of the diagnostic methods used by medical practitioners to identify the triggering allergens in patients is a skin prick test.
Via a prick to the skin, the patient is exposed to the suspected allergen and is monitored. After approximately 20 minutes, the skin is observed for any signs of reaction to one or several of the allergens: redness, swelling, itching.
Stallergenes Greer offers a broad portfolio of testing extracts which allow to test for a wide range of allergies. The company also offers testing devices.
Allergen immunotherapy
AIT is an allergy treatment designed to treat the underlying cause of the disease as well as have a long-lasting effect on all symptoms. After an accurate diagnosis of the type of allergy and responsible allergens, patients, in line with their healthcare practitioner’s prescription, receive a targeted treatment, available either in sublingual (tablets or drops) or subcutaneous (injections) form depending on product availability in each country.
Because it treats the root cause, AIT results in immunologic tolerance; i.e. a decrease in the body’s reaction to an allergen. Through the repeated administration of specific allergens to patients, the immune system builds resistance by changing the types and proportions of antibodies (immunoglobulins) and proteins (interleukins) it produces when it is exposed to the allergen, thus reducing symptoms when patients are exposed to the allergen in their environment – even after treatment ends. AIT usually requires 3 to 5 years of treatment1.
Our products
Whatever the options, Stallergenes Greer’s diagnostic and allergen immunotherapy treatments meet the most stringent clinical criteria, quality standards and health authorities’ regulatory requirements.
The market availability of Stallergenes Greer’s treatments varies according to each country.
Named patient products
Stallergenes Greer believes one solution does not fit all patients, hence we provide patients with personalised treatment options that are tailored to their individual needs. We aim to offer a comprehensive portfolio of AIT treatments globally which allow patients and their physicians to determine the administration method that best meets the disease and lifestyle needs of the patient.
The company’s allergen extracts cover a vast array of allergens. They can be produced in standardised form and can also be tailored to the specific needs of patients in terms of composition, concentration and dosage.
These personalised solutions, known as Named Patient Products (NPPs), are prepared according to the allergist’s prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollens, house dust mites, moulds...). Each NPP has its own biological activity and is prepared for the unique needs of an individual patient.
Sublingual
Staloral® (oral drops), for the treatment of allergy involving rhinitis, conjunctivitis, rhinoconjunctivitis or asthma (mild to moderate) of a seasonal or perennial nature, in adults and children (from the age of 5).
Actair®/ Orylmyte® (tablet), for the treatment of house dust mite allergies involving rhinitis, with or without conjunctivitis, in adults and adolescents over 12 years (and under 12 in certain territories).
Oralair® (tablet) contains a five-grass (sweet vernal, orchard, perennial rye, timothy, Kentucky blue grass) mixture, which represents many of the natural exposure and sensitisation conditions of grass pollen allergic patients.
Subcutaneous
Alustal®, for the treatment of allergic rhinitis, allergic rhinoconjunctivitis or mild to moderate asthma in adults and children.
Albey® venom, for the treatment of allergy to wasp, honeybee, and yellow jacket venoms.
Extracts and supplies
Stallergenes Greer manufactures a broad portfolio of allergen extracts and diagnostic tests.
- Bulk extracts
- Testing supplies : Alyostal Prick ®, Stallerpoint®, Prick Lancet®, the Greer® pick® system, Greer® pick®, Greer® pick® wellTM, Greer® pick® trayTM, Greer® pick® trayTM lid, 40-well Greer® pick® evaluation package, 60-well Greer® pick® evaluation package, Skintestor OmniTMsystem, Skintestor OmniTM, Skintestor OmniTM trays, 40- well skin OmniTM evaluation package, 60-well Skin OmniTM evaluation package
- Source materials and other supplies (sterile diluents, vials)
- GREER® ExtractsTM extracts are USDA approved for both subcutaneous and sublingual administration for veterinary use. Stallergenes Greer offers a wide selection of extracts and formulations.
- GREER® Sterile DiluentsTM various sizes, formulations, and fill volumes available
- GREER® Sterile Empty VialsTM a range of industryrelevant sizes for extract mixing and storage.
Veterinary use
From allergen testing to making precision treatment medicines, Stallergenes Greer is committed to providing veterinary specialists with products that can help treat animal allergies.
In the U.S., Stallergenes Greer offers a comprehensive range of allergen extracts and supplies for veterinary dermatologists to support the needs of their clients and pet patients.
Veterinary dermatologists are veterinarians that have specialised training in the management of allergic disease. They may use products from companies like Stallergenes Greer to compound named patient allergy products for dogs, cats, horses, and more.
Stallergenes Greer produces extracts of different strengths and formulations specifically for veterinary specialists.
1. Marogna M. et al., Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year study. J Allergy Clin Immunology, 2010)